Metabolomic biomarkers in blood samples identify cancers in a mixed population of patients with nonspecific symptoms
<strong>Purpose:</strong> Early diagnosis of cancer is critical for improving patient outcomes, but cancers may be hard to diagnose if patients present with nonspecific signs and symptoms. We have previously shown that nuclear magnetic resonance (NMR) metabolomics analysis can detect can...
Päätekijät: | Larkin, JR, Anthony, S, Johanssen, VA, Yeo, T, Sealey, M, Yates, AG, Smith, CF, Claridge, TDW, Nicholson, BD, Moreland, J-A, Gleeson, F, Sibson, NR, Anthony, DC, Probert, F |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
American Association for Cancer Research
2022
|
Samankaltaisia teoksia
-
Early diagnosis of brain metastases through biofluid metabolomics
Tekijä: Larkin, JR, et al.
Julkaistu: (2017) -
Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
Tekijä: Yeo, T, et al.
Julkaistu: (2019) -
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
Tekijä: Probert, F, et al.
Julkaistu: (2021) -
A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
Tekijä: Yeo, T, et al.
Julkaistu: (2020) -
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
Tekijä: Yeo, T, et al.
Julkaistu: (2022)